-
公开(公告)号：US11965029B2
公开(公告)日：2024-04-23
申请号：US17339301
申请日：2021-06-04
申请人： Amgen Inc.
发明人： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC分类号： C07K16/2866 , C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
摘要： Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US11059895B2
公开(公告)日：2021-07-13
申请号：US16242278
申请日：2019-01-08
申请人： Amgen Inc.
发明人： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
摘要： Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US10184002B2
公开(公告)日：2019-01-22
申请号：US15058104
申请日：2016-03-01
申请人： Amgen Inc.
发明人： Marc A. Gavin , Ai Ching Lim
摘要： The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
-
公开(公告)号：US20160251443A1
公开(公告)日：2016-09-01
申请号：US15058738
申请日：2016-03-02
申请人： KIRIN-AMGEN, INC.
发明人： Joel E. Tocker , Jacques J. Peschon , David Fitzpatrick , James F. Smothers , Christopher Mehlin , Ai Ching Lim
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
摘要翻译： 本发明涉及IL-17受体A（IL-17RA或IL-17R）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗IL-17受体介导的疾病的组合物和方法 一种或多种IL-17配体的活化。 本发明涉及鉴定IL-17受体A（IL-17RA或IL-17R）上的中和决定簇和与之结合的抗体。 本发明的方面还包括与本文所述的IL-17RA中和抗体竞争结合的抗体。
-
公开(公告)号：US09982054B2
公开(公告)日：2018-05-29
申请号：US15178652
申请日：2016-06-10
申请人： Amgen Inc.
发明人： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
摘要： Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US20140356355A1
公开(公告)日：2014-12-04
申请号：US14304472
申请日：2014-06-13
申请人： Amgen Inc.
发明人： Joel E. Tocker , Jacques J. Peschon , David Fitzpatrick , James F. Smothers , Christopher Mehlin , Ai Ching Lim
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
摘要翻译： 本发明涉及IL-17受体A（IL-17RA或IL-17R）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗IL-17受体介导的疾病的组合物和方法 一种或多种IL-17配体的活化。 本发明涉及鉴定IL-17受体A（IL-17RA或IL-17R）上的中和决定簇和与之结合的抗体。 本发明的方面还包括与本文所述的IL-17RA中和抗体竞争结合的抗体。
-
公开(公告)号：US11976103B2
公开(公告)日：2024-05-07
申请号：US17065395
申请日：2020-10-07
申请人： Amgen Inc.
发明人： Eric Alan Butz , Christy Ann Thomson , Marc Alain Gavin , Ian Nevin Foltz , Dong Xia , Dina N. Alcorn , Randal Robert Ketchem , Ai Ching Lim , Kathy Manchulenko , Laura Sekirov , Kelly Ann Berry , Cyr Clovis Chua De Imus , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Li Li
CPC分类号： C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US10851144B2
公开(公告)日：2020-12-01
申请号：US15565376
申请日：2016-05-04
申请人： AMGEN INC.
发明人： Eric Alan Butz , Christy Ann Thomson , Marc Alain Gavin , Ian Nevin Foltz , Dong Xia , Dina N. Alcorn , Ai Ching Lim , Randal Robert Ketchum , Kathy Manchulenko , Laura Sekirov , Kelly Ann Berry , Cyr Clovis Chua De Imus , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Li Li
摘要： Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US10227414B2
公开(公告)日：2019-03-12
申请号：US15601868
申请日：2017-05-22
申请人： Amgen Inc.
发明人： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
摘要： Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US09382318B2
公开(公告)日：2016-07-05
申请号：US13897096
申请日：2013-05-17
申请人： Amgen Inc.
发明人： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
摘要： Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
摘要翻译： 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物及其变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.027 秒)
